title: Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface.
abstract: When bacterial lipopolysaccharide (LPS) enters the bloodstream, it is thought to have two general fates. If LPS binds to circulating leukocytes, it triggers innate host defense mechanisms and often elicits toxic reactions. If instead LPS binds to plasma lipoproteins, its bioactivity is largely neutralized. This study shows that lipoproteins can also take up LPS that has first bound to leukocytes. When monocytes were loaded with [(3)H]LPS and then incubated in plasma, they released over 70% of the cell-associated [(3)H]LPS into lipoproteins (predominantly high density lipoprotein), whereas in serum-free medium the [(3)H]LPS remained tightly associated with the cells. The transfer reaction could be reproduced in the presence of pure native lipoproteins or reconstituted high density lipoprotein. Plasma immunodepletion experiments and experiments using recombinant LPS transfer proteins revealed that soluble CD14 significantly enhances LPS release from the cells, high concentrations of LPS-binding protein have a modest effect, and phospholipid transfer protein is unable to facilitate LPS release. Essentially all of the LPS on the monocyte cell surface can be released. Lipoprotein-mediated LPS release was accompanied by a reduction in several cellular responses to the LPS, suggesting that the movement of LPS from leukocytes into lipoproteins may attenuate host responses to LPS in vivo.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235-9113, USA. rkitch@mednet.swmed.edu
authors.forename: R L
authors.initials: RL
authors.lastname: Kitchens
authors.forename: G
authors.initials: G
authors.lastname: Wolfbauer
authors.forename: J J
authors.initials: JJ
authors.lastname: Albers
authors.forename: R S
authors.initials: RS
authors.lastname: Munford
mesh_terms: D000209:Acute-Phase Proteins; D002352:Carrier Proteins / Q000494:pharmacology; D002460:Cell Line; D016895:Culture Media, Serum-Free / Q000494:pharmacology; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000378:metabolism / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000097:blood* / Q000378:metabolism; D008074:Lipoproteins / Q000097:blood* / Q000378:metabolism / Q000494:pharmacology; D008075:Lipoproteins, HDL / Q000494:pharmacology; D008562:Membrane Glycoproteins; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism*; D011485:Protein Binding; D011994:Recombinant Proteins / Q000494:pharmacology; D014316:Tritium; D000099231:Lipopolysaccharide-Binding Protein
chemical_list: D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D016895:Culture Media, Serum-Free; D016207:Cytokines; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins; D014316:Tritium; D000099231:Lipopolysaccharide-Binding Protein